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ABSTRACT
The interaction between the acidic transactivation
domain of the human tumor suppressor protein p53
(p53TAD)andthe70kDasubunitofhumanreplication
protein A (hRPA70) was investigated using hetero-
nuclear magnetic resonance spectroscopy. A
1H–
15N
heteronuclear single quantum coherence (HSQC)
titration experiment was performed on a
15N-labeled
fragment of hRPA70, containing the N-terminal 168
residues (hRPA701–168) and p53TAD. HRPA701–168
residues important for binding were identified and
found to be localized to a prominent basic cleft.
This binding site overlapped with a previously iden-
tified single-stranded DNA-binding site, suggesting
that a competitive binding mechanism may regulate
the formation of p53TAD–hRPA70 complex. The
amide
1H and
15N chemical shifts of an uniformly
15N-
labeledsampleofp53TADwerealsomonitoredbefore
andaftertheadditionofunlabeledhRPA701–168.Inthe
presence of unlabeled hRPA701–168, resonance line-
shapesincreasedandcorrespondingintensityreduc-
tions were observed for specific p53TAD residues.
The largest intensity reductions were observed for
p53TAD residues 42–56. Minimal binding was
observed between p53TAD and a mutant form of
hRPA701–168, where the basic cleft residue R41 was
changed to a glutamic acid (R41E), demonstrating
that ionic interactions play an important role in spe-
cifying the binding interface. The region of p53TAD
most affected by binding hRPA701–168 was found to
have some residual alpha helical and beta strand
structure; however, this structure was not stabilized
by binding hRPA701–168.
15N relaxation experiments
were performed to monitor changes in backbone
dynamics of p53TAD when bound to hRPA701–168.
Largechangesinboththetransverse(R2)androtating
frame (R1r) relaxation rates were observed for a sub-
set of the p53TAD residues that had
1H–
15N HSQC
resonance intensity reductions during the complex
formation. The folding of p53TAD upon complex
formation is suggested by the pattern of changes
observed for both R2 and R1r. A model that couples
the formation of a weak encounter complex between
p53TAD and hRPA701–168 to the folding of p53TAD
is discussed in the context of a functional role
for the p53–hRPA70 complex in DNA repair.
INTRODUCTION
To promote the preservation and damage-free replication of
genomic DNA, a complex system of proteins that can efﬁ-
ciently recognize and repair the most frequently occurring
types of DNA damage has evolved (1–4). The four principle
DNA repair systems for eukaryotic genomes are base excision
repair, mismatch repair, nucleotide excision repair and recom-
binational repair. In humans, the four DNA repair systems
share many features, including overlapping substrate speciﬁ-
city and proteins that are used in multiple repair pathways
(3,5). Human replication protein A (hRPA) is a heterotrimeric
single-stranded (ssDNA)-binding protein that is required for
base excision repair, nucleotide excision repair and recom-
binational repair (3,5,6). HRPA is composed of 32 kDa
(hRPA32), 14 kDa (hRPA14) and 70 kDa (hRPA70) subunits
(7,8).AlinearschematicrepresentationofthehRPA70 subunit
is shown at the top of Figure 1. The ﬁrst 180 residues of
hRPA70 consists of a structured domain that forms an oligo-
nucleotide binding fold known as DNA-binding domain F
(DBD F) (residues 1–105) and a ﬂexible linker (residues
106–180) (9). DBD F contains a weak ssDNA-binding site
that is localized to a prominent basic cleft (9,10). The posit-
ively charged residues comprising the basic cleft are under-
lined in the hRPA70 primary sequence for residues 1–168
(Figure 1). DBD F is also the site for many of the interactions
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doi:10.1093/nar/gki336that occur between hRPA70 and other proteins during DNA
metabolism (9,11–14). The ﬂexible linker connects DBD F to
two tandem, high-afﬁnity ssDNA-binding domains (DBD A
and B, residues 181–422) that also have oligonucleotide bind-
ing topologies (15). C-terminal of DBD B is a domain that is
important for dimerization with hRPA32 and this domain may
also participate in the recognition of the bulky DNA adducts
that are repaired during nucleotide excision repair (DBD C,
residues 423–614) (5,15–19).
HRPA has numerous protein-binding partners that are
important for its functions during DNA repair (5,13,20).
One protein that binds hRPA is the human tumor suppressor
protein, p53 (13,21–24). The hRPA–p53 complex disassoci-
ates in response to DNA damage and in the presence of ssDNA
(21,24). It is hypothesized that the hRPA–p53 complex pro-
vides a reservoir of p53 that is immediately available during
the early stages of DNA repair (24). The p53 protein regulates
the cell cycle in response to a variety of stress signals, prim-
arily through direct transcriptional activation or repression of
speciﬁc target genes (25–27). The speciﬁc stress signal as well
as the cell type and context will dictate whether p53 induces
transient growtharrest, or senescence orapoptosis. In response
to UV radiation, p53 induces a transient growth arrest that
provides the DNA repair machinery the necessary time to
repair the damage. After repair is completed, there is a c-Jun-
mediated exit back to the cell cycle (28). It also appears that
p53 can play a more direct role in DNA repair and replication
(29,30). Figure 1 shows a linear schematic representation of
p53 containing ﬁve functional domains, the transactivation
domain (TAD) (residues 1–73), the polyproline region (PP)
(residues 62–91), the sequence-speciﬁc DBD (residues 102–
292), the tetramerization domain (TD) (residues 320–356) and
the regulatory domain (RD) (residues 363–393). The TAD
contains several sites for phosporylation, some of which pre-
vent p53 from targeted degradation (31). The PP domain con-
tains ﬁve partially conserved PXXP repeats and is necessary
for efﬁcient growth suppression (32). The DBD is responsible
for site-speciﬁc DNA binding and is the domain where many
cancer associated mutations are found (33,34). The TD is
essential for p53 tetramerization, which appears to be neces-
sary for the phosphorylation of certain sites in the TAD but not
for site-speciﬁc DNA binding (35). The RD is thought to
regulate the function of the DBD (27). The p53 DBD and
TD have been well characterized at a molecular level by
NMR and X-ray crystallography (36–40). Conversely, the
TAD and RD are not well characterized at a structural level.
Approximately 50% of full-length p53 is unfolded under
native conditions (41,42). The TAD is one such unstructured
region (43,44). The ability of intrinsically unstructured pro-
teins (IUPs) to participate in the complex regulatory processes
is becoming a new paradigm in molecular biology (41). It is
hypothesized that IUPs are pliable and able to remodel their
structures to interact with multiple protein partners (45,46).
Afﬁnity chromatography and mutational studies have
shown that hRPA70 and not hRPA32 or hRPA14 interacts
with p53 (13,22,23). Further, deletion analysis has shown
that hRPA70 residues 1–221 are important for this interaction
(16). In addition, this study also showed that hRPA70 residues
Figure 1. Linear schematic diagrams showing the functional domains of hRPA70 and p53. Beneath the schematic diagrams are the primary sequences of
hRPA701–168 and p53TAD. The hRPA701–168 basic cleft residues and the p53TAD negatively charged residue pairs are underlined in each sequence.
2062 Nucleic Acids Research, 2005, Vol. 33, No. 7411–492 can interact with full-length p53, but with a lower
afﬁnity than residues 1–221. A series of mutational studies
identiﬁed regions near the N- and C-termini of p53 that are
involved in binding hRPA70 (21–23,47). Truncated versions
of p53 consisting of residues 2–71 and 289–356 are able to
form a complex with hRPA70 (47). However, four truncated
versions of p53 consisting of residues 2–45, 46–71, 289–330
and 331–356 do not bind hRPA70 (47). These studies also
showed that p53 residues 40–60 were essential for the forma-
tion of the p53–hRPA70 complex (21,47). While the deletion
studies reviewed in this section identiﬁed speciﬁc regions of
either p53 or hRPA70 that are necessary for complex forma-
tion with the full-length counterpart, they did not identify
the minimal domains of both proteins that are sufﬁcient for
complex formation. In this study, we present evidence for a
direct interaction between the transactivation domain of p53
(residues 1–73, p53TAD) and a fragment of hRPA70 contain-
ing DBD F and most of the ﬂexible linker (residues 1–168,
hRPA701–168). Site-directed mutations localized to the DBD F
and the ﬂexible linker were investigated revealing an hRPA70
motif that is essential for complex formation. Further,
hRPA701–168 and p53TAD chemical shift maps are presented,
identifying the binding interface for this interaction. This
report also includes a detailed examination of the secondary
structure and dynamics of p53TAD in the presence and
absence of hRPA701–168. In particular, changes in backbone
dynamics that occur for speciﬁc p53TAD residues upon bind-
ing hRPA701–168 suggest a mechanism where the folding of
p53TAD is coupled to binding hRPA701–168.
MATERIALS AND METHODS
Media
All growth experiments were performed in M9 media. For the
production of isotopically labeled samples 1 g/l of
15N-labeled
ammonium chloride and/or 0.2% (w/v)
13C-labeled glucose
were added in the place of nitrogen and carbon sources
(Cambridge Isotopes). All cells were grown at 37 C.
Expression and purification of p53TAD
A plasmid containing the complete human p53 cDNA was
obtained from Dr Lee Fortunato (University of Idaho). The
genetic sequence for residues 1–73 of human p53 was
ampliﬁed by the PCR usingtwo primers d(CGACAAGCATA-
TGATGGAGGAGCCGCAGTCA) and d(AAATCCTCGAG-
TCACACGCGGGGAGCAGC). The product of this reaction
was digested with NdeI at the 50 end and XhoI at the 30 end
and subcloned into pET28a (Novagen). This yielded a vector
where residues 1–73 of human p53 could be expressed with an
N-terminal 7-histidine tag and a thrombin cleavage site. The
identity of this clone was veriﬁed by DNA sequencing.
The p53/pET28a clone was transformed into Ca
2+-treated
Escherichia coli BL21(DE3) cells using the heat-shock
method (Novagen). Single colonies from this transforma-
tion were used to inoculate 50 ml cultures of M9 media that
were grown overnight. The overnight cultures were then
re-inoculated into 2 L of M9 media at an A600 of 0.03. These
cultureswere inducedatanA600of0.7with 1mMisopropyl-b-
D-thiogalactopyranoside and grown for 6 h. The pelleted cells
were resuspended in 35 ml of lysis buffer (50 mM NaH2PO4,
300 mM NaCl, 10 mM imidazole and 0.02% NaN3, pH 8.0)
containing protease inhibitors (Sigma) and lysed using a
French press. The clariﬁed lysate was loaded onto a column
containing 30 ml of NiNATA Superﬂow resin (Qiagen) that
had previously been equilibrated with 5 column volumes of
lysis buffer. All buffers used on the NiNATA column were run
at a ﬂow rate of 3 ml/min. The column was washed with
2 column volumes of wash buffer (50 mM NaH2PO4,
300 mM NaCl, 20 mM imidazole and 0.02% NaN3,p H
8.0) and the p53 eluted with 3 column volumes of elution
buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole,
0.02 % NaN3, pH 8.0). Fractions were analyzed using PAGE
and those containing the protein were combined and dialyzed
into the gel ﬁltration buffer (50 mM NaH2PO4, 300 mM NaCl,
1mM EDTAand0.02%NaN3,pH7.0)using3500DaMWCO
dialysis tubing (Spectrapor). The p53 protein was then con-
centrated in a centriprep YM3 (Amicon) and the histidine tag
cleaved by thrombin (thrombin clean cleave kit, RECOM-T;
Sigma). To achieve optimal cleavage, the protein was incub-
ated with thrombin for 2 h at room temperature. The comple-
tion of the cleavage reaction was veriﬁed using PAGE. The
p53 protein was then loaded onto a HiLoad 16/60 Superdex 75
prep grade column (Pharmacia). The column was equilibrated
and the protein eluted with gel-ﬁltration buffer at a ﬂow rate of
1.5 ml/min. Protein purity was veriﬁed using PAGE analysis.
The puriﬁed p53 protein was dialyzed into the NMR experi-
ment buffer; 50 mM NaH2PO4, 50 mM NaCl, 1 mM EDTA
and 0.02% NaN3 and 1 mM DTT, pH 6.5 and concentrated in a
YM3 centriprep/centricon (Amicon).
Expression and purification of hRPA701–168
Expression and puriﬁcation of hRPA701–168 was based on a
published protocol (48). A clone containing the cDNA cor-
responding to amino acid residues 1–168 of hRPA70 in pet11d
(hRPA701–168) was described previously (12). E.coli
BL21DE3 cells containing the hRPA701–168 plasmid were
used to inoculate a 50 ml overnight culture. This culture
was diluted into 2 L M9 media at A600 of 0.03. The 2 L culture
was induced with 1 mM isopropyl-b-D-thiogalactopyranoside
at an A600 of 0.6 and grown for 3 h. Pelleted cells were resus-
pended in HI buffer [30 mM HEPESfrom a 1 M HEPESstock,
pH 7.8, 0.25 mM EDTA, 0.25% (w/v) inositol, 0.01% (v/v)
IGEPAL and 1 mM DTT] containing 50mM KCl and protease
inhibitors (Sigma). The resuspended cells were lysed using a
French press and the supernatant was isolated by centrifuga-
tion. The supernatant was loaded onto a column containing
30 ml of Afﬁ-gel blue resin (Biorad) equilibrated with 5 col-
umn volumes of HI buffer containing 50 mM KCl. All buffers
used on this column were at a ﬂow rate of 3 ml/min. The
column was washed sequentially with 4 column volumes of
HI buffer plus 0.8 M KCl, 4 column volumes of HI buffer plus
0.5 M NaSCN, 3 column volumes of HI buffer plus 1.0 M
NaSCN and 3 column volumes of HI buffer plus 1.5 M
NaSCN. The protein is eluted in the 1.5 M NaSCN step.
The fractions were analyzed using PAGE and fractions con-
taining hRPA701–168 were pooled and dialyzed into the gel
ﬁltration buffer (50 mM NaH2PO4, 1 mM EDTA, 300 mM
NaCl and 0.02% NaN3, pH 7.0). The protein was further
puriﬁed on a size exclusion column (HiLoad 16/60 Superdex
Nucleic Acids Research, 2005, Vol. 33, No. 7 206375 prep grade column; Pharmacia) using the gel-ﬁltration
buffer. Following gel ﬁltration, hRPA701–168 purity was
determined using PAGE. Fractions containing hRPA701–168
were dialyzed into the NMR experiment buffer and concen-
trated using a YM10 centriprep/centricon (Amicon).
Two mutants containing single amino acid changes were
made in the hRPA701–168 clone described above. The clones
contained either an Y118A or a R41E mutation and are
referred to as Y118A and R41E. The mutations were made
by following the procedure outlined in the Stratagene Site
Directed Mutagenesis Kit and the identity of each clone
was veriﬁed by DNA sequencing. Y118A and R41E were
overexpressed and puriﬁed using the same method as
described for hRPA701–168.
NMR data collection and analysis
All NMR experiments were performed on a Varian Inova
spectrometer operating at a
1H resonance frequency of
600 MHz and a sample temperature of either 278 or 298K.
To make the amide
1H and
15N as well as
13C
a,
13C
b and
13CO
resonance assignments, sensitivity enhanced HNCACB and
HNCO experiments were performed on a 0.30 mM uniformly
15N and
13C labeled sample of p53TAD in 90% H2O/10% D2O
using the NMR experiment buffer (49–51). For the HNCACB
experiment, data in the
1H dimension was acquired using a
sweep width of 8000 Hz and 512 complex t3 points, data in the
13C dimension were acquired using a sweep width of 12 065.5
Hz and 128 complex t1 points, and data in the
15N dimension
wereacquiredusing asweep widthof1400Hz and32complex
t2 points. For the HNCO, experimental parameters were ident-
ical to the
1H and
15N dimensions of the HNCACB. Data in the
13C dimension of the HNCO were acquired using a sweep
width 3017.1 Hz and 64 complex t1 points. Processing and
analysis of the HNCACB data resulted in 60 non-proline,
amide
1H,
15N,
13C
a and
13C
b resonance assignments plus
12 proline
13C
a and
13C
b resonance assignments. Processing
and analysis of the HNCO data resulted in 59
13CO resonance
assignments.The
1H
a resonance assignmentswere made using
the 3D
15N-edited TOCSY-heteronuclear single quantum
coherence (HSQC) experiment and a 0.30 mM uniformly
15N-labeled sample of p53TAD (52). For the TOCSY-
HSQC experiment, data in the direct
1H dimension were
acquired using a sweep width of 8000 Hz and 512 complex
t3 points, data in the indirect
1H dimension were acquired with
a sweep width of 8000 Hz and 128 complex t1 points and data
in the
15N dimension were acquired with a sweep width of
1400 Hz and 32 complex t2 points. Processing and analysis of
the TOCSY-HSQC data resulted in 59 non-proline
1H
a res-
onance assignments. The hRPA701–168 resonance assignments
were described previously (9).
Forthep53TADandhRPA701–168titrationexperiments,2D,
gradient enhanced,
1H–
15N HSQC spectra were acquired on
uniformly
15N-labeled samples of p53TAD and hRPA701–168
in NMR experiment buffer (49,53). For the p53TAD
1H–
15N
HSQC experiments, data in the
1H dimension were acquired
using asweepwidthof8000Hz and512 complex t2pointsand
data in the
15N dimension were acquired using a sweep width
of 1140 Hz and 128 complex t1 points. For the hRPA701–168
1H–
15N HSQC experiments, data in the
1H dimension were
acquired using a sweep width of 8000 Hz and 512 complex
t2 points and data in the
15N dimension were acquired using a
sweep width of 2200 Hz and 128 complex t1 points. Titrations
were performed using a 0.30 mM uniformly
15N-labeled sam-
ple of p53TAD in 90% H2O/10% D2O in the NMR experiment
buffer. Unlabeled hRPA701–168 at a stock concentration of
0.45 mM was added to the p53TAD sample to concentrations
of 0.005, 0.010, 0.050, 0.10, 0.15 and 0.30 mM. After each
addition of unlabeled hRAP701–168,a
1H–
15N HSQC spectrum
was collected using the same parameters described above.
When enough unlabeled hRAP701–168 was added to increase
the total sample volume by 10%, the sample was removed
from the NMR tube and concentrated to the original volume
(600 ml) using a YM3 centricon. The reverse titration was
performed using a 0.60 mM uniformly
15N-labeled sample
of hRPA701–168 in 90% H2O/10% D2O in the NMR experi-
ment buffer. Unlabeled p53TAD at a stock concentration of
0.45 mM was added to the p53TAD sample to concentrations
of 0.005, 0.010, 0.050, 0.10, 0.15, 0.30 and 0.60 mM. Other
experimental conditions were identical to those used for the
15N-labeled p53TAD titration. Similar results were observed
for titrations both at 278 and at 298K.
All NMR spectra were processed and analyzed using the
Felix software from the Accelerys Corporation (Cambridge,
MA). Apodization was achieved in the
1H,
13C and
15N dimen-
sions using a squared sine bell function shifted by 90 . Apod-
ization was followed by zero ﬁlling to twice the number of real
data points and mirror image linear prediction was used in the
15N dimension of the HNCACB. Amide
1H,
15N and
13C
chemical shift and resonance peak height measurements
were made using the Felix program and converted into tab-
delimited ASCII ﬁles. Intensity ratio plots were generated
using the KaleidaGraph software from Synergy (Reading,
PA). The referencing method used in this report is based on
IUPAC recommendations for using DSS in a highly polar
solvent, such as water (54,55).
Relaxation data collection
The relaxation experiments for free p53TAD were acquired at
298K on 0.30 mM uniformly
15N-labeled sample at pH 6.5 in
NMR experiment buffer. In addition, the relaxation experi-
ments for bound p53TAD were acquired under the same
conditions after the addition of unlabeled hRPA701–168 to a
concentration 0.075mM.Thespin-lattice relaxationrates (R1),
spin–spin relaxation rates (R2), rotating frame relaxation
rates (R1r) and
1H–
15N NOEs were measured by inverse-
detected 2D NMR methods (56). The spin-lattice relaxation
rates were determined by collecting 10 2D spectra using
relaxation delays of 10, 50, 110, 190, 310, 500, 650, 1000,
1500and 1900 ms. Thespin–spin relaxationrates androtating-
frame relaxation rates were each determined by collecting 10
2D spectra using relaxation delays of 10, 30, 50, 90, 110, 150,
190, 210, 230 and 250 ms. A 70 , off-resonance, spinlock
pulse with a ﬁeld strength of 1.5 kHz was used for the R1r
experiments. Peak heights from each series of relaxation
experiments were ﬁtted to a single decaying exponential func-
tion.Tomeasurethe
1H–
15NNOEsonespectrumwasacquired
with a 3 s mixing time for the NOE to build up and the another
spectrum was acquired with a 3 s recycle delay for a reference.
For all experiments water suppression was achieved by using
pulsedﬁeld gradients. TheR1,R2,R1rand
1H–
15NNOE values
2064 Nucleic Acids Research, 2005, Vol. 33, No. 7were determined for all 60 non-proline resonances of free
p53TAD and 58 non-proline resonances for p53TAD bound
to hRAP701–168. Relaxation data were not determined for E51
and Q52 in p53TAD bound to hRAP701–168 owing to weak
resonance intensities. In addition, resonances for W53 and F54
overlap in both free and bound p53TAD at 298K and the
relaxation data presented for these residues are an average
value. A similar condition exists for Q16 and R72. Uncertain-
ties in measured peak heights were estimated from baseline
noise level and were typically <1% of the peak heights from
the ﬁrst R1, R2 and R1r delay points. In general, ﬁtting errors
were within 10% of the calculated relaxation rates.
Relaxation data analysis
Relaxation data were analyzed using the reduced spectral
density mapping approach (57–60). The
15N chemical shift
anisotropy and the dipolar coupling between the amide
15N
nucleus and the attached proton have the greatest inﬂuence on
the
15N nuclear relaxation (61). The values for R1, R2 and the
NOE between the amide proton and the nitrogen are related to
the spectral density using the following relationships:
R1¼
d2
4
  
3J wN ðÞ þ 6J wHþwN ðÞ þ J wH  wN ðÞ ½  þ c2J wN ðÞ ‚
1
R2¼
d2
8
  
4J 0 ðÞ þ 3J wN ðÞ þ 3J wHþwN ðÞ þ 6J wH ðÞ ½
þJ wH  wN ðÞ   þ
c2
6
  
J 0 ðÞ þ 6J wN ðÞ ½  þ Rex‚ 2
NOE¼1þ
d2
4R1
  
gH
gN
  
6J wHþwN ðÞ   J wH  wN ðÞ ½  ‚ 3
where d¼ðm0hgHgN=8p2Þhr 3
NHiand c¼wNDs=
ﬃﬃﬃ
3
p
, m0 is the
permeability of free space, h is the Planck’s constant, gH
and gN are the gyromagnetic ratios of
1Ha n d
15N,
respectively, rNH is the amide bond length (1.02 s), Ds is
the chemical shift anisotropy ( 160 p.p.m.) and Rex is the
chemical exchange contribution to R2.J ( w) is the power
spectral density function defining the reorientation of the
N–H bond vector by stochastic (global) and intramole-
cular motions. Reduced spectral density mapping uses an
average value of J(wH) for the linear combinations of
J(wH +w N), J(wH) and J(wH   wN) leading to the values of
J(0), J(wN)a n dJ ( wH) that are given by:
sNH¼R1 NOE 1 ðÞ
gN
gH
: 4
J wH ðÞ ¼
4sNH
5d2 : 5
J wN ðÞ ¼
4R1  5sNH ½ 
3d2þ4c2    : 6
J 0 ðÞ ¼
6R2  3R1  2:72sNH ½ 
3d2þ4c2    : 7
This approach estimates the magnitude of the spectral density
function at the given frequencies, making no assumptions
about the form of the spectral density function or about the
molecular behavior giving rise to the relaxation.
RESULTS AND DISCUSSION
NMR evidence for overlapping ssDNA- and
p53TAD-binding sites on DBD F
The identiﬁcation of minimal interacting domains for hRPA70
and p53 is a necessary step toward understanding the mech-
anism of p53–hRPA70 complex formation and disassociation.
To test if hRPA701–168 and p53TAD are sufﬁcient for complex
formation, a
1H–
15N HSQC titration experiment was per-
formed on
15N-labeled hRPA701–168. The amide
1H–
15N
HSQC resonances were monitored for a uniformly
15N-labeled
0.60 mM sample of hRPA701–168 before and after the addition
of unlabeled p53TAD to concentrations of 0.005, 0.01, 0.05,
0.10, 0.15, 0.30 and 0.60 mM. Chemical shift changes were
observed after the addition of p53TAD to a concentration of
0.05 mM. Figure 2shows a representative proﬁle for one of the
resonances most affected by binding. Figure 2 shows the res-
onances forA59 from overlapping
1H–
15N HSQC spectraafter
the addition of p53TAD to concentrations of 0.0, 0.05, 0.10,
0.15, 0.30 and 0.60 mM. The starting position of the A59
resonance is indicated by the red box and crosshair. Arrows
with p53TAD concentration values show the movement of the
A59 resonance during the course of the titration. The small
chemical shift changes observed between the last two points in
the titration series indicates that the binding is approaching
saturation. These results demonstrate that the p53TAD and
Figure 2. Overlapping
1H–
15N HSQC spectra for A59 and A128 resonances
obtained during titration between hRPA701–168 and p53TAD.A59 participates
in binding while A128 does not. Spectra were collected at 298K.
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Figure 2 also shows the resonance for A128, which experi-
ences no chemical shift changes during the course of the
titration.
The ability to track the chemical shift changes during the
course of a titration permits assignment of the bound reson-
ances based on the assumptionof a minimal perturbation in the
spectra. This process was used to make the amide
15N and
1H
resonance assignments for the bound form of hRPA701–168.
The amide
15N and
1H chemical shift changes observed
between free hRPA701–168 and hRPA701–168 in the presence
of 0.60 mM p53TAD were tabulated and averaged to identify
the hRPA701–168 residues that are most affected by binding to
p53TAD. The mean value for the averaged amide
15N and
1H
chemical shift changes for residues M1-L122 of hRPA701–168
is 0.03 p.p.m. and the resolution for this measurement
is 0.02 p.p.m. Chemical shift changes are not observed for
hRPA701–168 residues that are C-terminal of L122. Small
(<0.01 p.p.m.) or no chemical shift changes are observed
for the majority of hRPA701–168 residues from M1-L122.
HRPA701–168 residues with average chemical shift changes
>0.05 p.p.m. are G17, I30, I33, T35, G36, L45, S54, S55, F56,
A59, T86, L87, R91, R92, V93, E98 and Y118.
Figure 3a shows a ribbon diagram of hRPA70 residues
1–114, which includes the DBD F and a short segment of the
ﬂexible linker. In Figure 3a, the positions of hRPA701–168
residues with chemical shift changes that are >0.05 p.p.m.
following the p53TAD titration are colored red. The side
chains and labels are shown for the arginine and lysine resi-
dues that form the basic cleft. With the exception of G17 and
E98, all of the hRPA701–168 residues that have chemical shift
changes >0.05 p.p.m.whenbound to p53TADare within 15 s
of the basic cleft. The chemical shift changes observed for the
other basic cleft residues are as follows: R31 = 0.02 p.p.m.,
R41 = 0.03 p.p.m.and R43 = 0.04 p.p.m.Chemical shift values
were not measured for K88 owing to resonance overlap.
In a previous study, an NMR titration strategy was used to
identify a weak ssDNA-binding site that was also localized to
the DBD F basic cleft (10). Figure 3b shows a ribbon diagram
of DBD F with the hRPA701–168 residues that experienced the
largest chemical shift changes after the addition of ssDNA
colored red (10). These residues are T34, T35, R41, Y42,
A59-L62, T86, D89, R91, V93 and Y118. Chemical shift
changes were not observed for residues C-terminal of L122.
In Figure 3b, all of the hRPA701–168 residues that have the
largest chemical shift changes when bound to ssDNA are also
within 15 s of the basic cleft. A comparison of Figure 3a and b
shows that p53TAD and ssDNA occupy overlapping but
non-identical binding sites on DBD F. This conclusion is
emphasized in Figure 3c, which shows the position of the
hRPA701–168 residues that experience the largest chemical
shift changes after the addition of either p53TAD or
ssDNA. The position of these residues is shown relative to
the linear sequence and secondary structure for hRPA70
residues 1–123.
The localization of the p53TAD (pI = 3.77) and ssDNA-
binding sites to the DBD F basic cleft is expected since both
molecules are negatively charged. The presence of overlap-
ping p53TAD and ssDNA-binding sites on DBD F suggests
that a competitive binding mechanism may regulate complex
Figure 3. (a)RibbondiagramofDBDFshowingthepositiononthestructureofresidueswiththelargestchemicalshiftchangesuponbindingp53TADcoloredred.
(b)RibbondiagramofDBDFshowingthepositiononthestructureofresidueswiththelargestchemicalshiftchangesuponbindingssDNAcoloredred.For(a)and
(b),theN-andC-terminiandthepositivelychargedresiduesthatformtheDBDFbasiccleftarelabeled.(c)Schematicrepresentationofthesecondarystructureand
linearsequenceforhRPA70residues1–123.b-Strandsarelabeledwitharrows,a-helicesarelabeledwithcylinders,andloopandcoilregionsarelabeledwithlines.
Thea3helixiscoloredgraytoreflectitsreducedstability(9).ShowninredbelowthesequencearethehRPA701–168residueswiththelargestchemicalshiftchanges
upon binding either p53TAD or ssDNA.
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of the hRAP70–p53 complex that occurs in response to DNA
damage (21,24). While the afﬁnity of p53TAD or ssDNA for
DBD F has not been directly measured, an upper limit on the
association constant can be inferred from the behavior of the
resonance lines during the course of the titrations. For both
titrations, the resonance lines in the DBD F
1H–
15N HSQC
spectra undergo chemical shifts that vary continuously with
ligand concentration and the trajectories of these chemical
shifts are linear and occur at the same rate for all residues
thatformthebindinginterfaces.Whenresonancelinesundergo
chemical shifts that vary continuously with ligand concentra-
tion, the bimolecular association constant, Ka, will be on the
order of 10
5 (62).In addition, if the trajectories of the chemical
shift changes are linear and occur at the same rate for all the
residues that form the binding interface, then a single binding
event is probable.
Identification of p53TAD residues important for
binding hRPA701–168
1H–
15N HSQC experiments were also performed on uniformly
15N-labeled samples of p53TAD before and after the addition
of increasing amounts of unlabeled hRPA701–168. The left
panel of Figure 4 shows a selected region of the assigned
1H–
15N HSQC spectrum of a 0.30 mM sample of p53TAD
and the right panel shows the
1H–
15N HSQC spectrum of the
same sample after the addition of unlabeled hRPA701–168 to a
concentration of 0.30 mM. In both spectra, the
1H chemical
shifts are plotted on the horizontal axis. The
15N chemical
shifts are plotted on the vertical axis of the spectrum on the
right. The observed spectral changes that occurred after the
addition of unlabeled hRPA701–168 are characterized by
resonance intensity reductions and some small chemical shift
changes. Owing to the interaction between hRPA701–168 and
p53TAD, the resonances for residues 43–56 become so weak
they can no longer be detected.
Resonance intensity measurements were made for 58 of the
assigned non-proline residues in both of the Figure 4 spectra.
An intensity ratio was calculated by dividing the resonance
intensities of free p53TAD by the resonance intensities of
p53TAD after the addition of hRPA701–168. Owing to the
overlap of the D42 and M44 resonances and the W53 and
F54 resonances these measurements represent an average
value. The intensity ratios for the p53TAD resonances are
plotted in Figure 5a. The log10 of the intensity ratio is plotted
on the vertical axis andthe residue type and numberare plotted
on the horizontal axis. Figure 5a shows that residues 39–59
have the largest resonance intensity changes in the presence of
hRPA701–168 with residues 42–56 having intensity ratios that
are >10. These data corroborate earlier afﬁnity binding studies
which suggested that residues 40–60 are essential for binding
hRPA70 (21,47).
The residues adjacent to the 39–59 region of p53TAD
showed some reduction in resonance intensities with residues
35–38 and 61–62 having mean intensity ratios of 3.5 – 0.28
and 3.2 – 0.19, respectively. A second region, including resi-
dues 19–28, had a mean intensity ratio of 3.5 – 0.46. This
region contains a transient amphipathic helix (43). Previous
studies showed that mutations at residues 22 and 23 had minor
effects on binding to hRPA70 (21). These previous results are
consistent with the data in Figure 5a, which show that residues
19–28 contribute to binding hRPA701–168 but to a much smal-
ler extent than residues 39–59. It was also previously reported
Figure 4. Selected regions of the assigned
1H–
15N HSQC spectra of 0.30 mM uniformly
15N-labeled p53TAD. The left panel shows p53TAD alone and the right
panel shows p53TAD after the addition of unlabeled hRPA701–168 to a concentration of 0.30 mM. Both spectra were collected at 278K.
Nucleic Acids Research, 2005, Vol. 33, No. 7 2067that two truncated versions of p53, consisting of residues 2–45
and 46–71, do not bind hRPA70 (47). This result is easily
explained by the data in Figure 5a, which clearly show that
both these truncated constructs eliminate residues that contrib-
ute strongly to the binding of hRPA701–168.
Importance of DBD F basic cleft residue R41 for
complex formation
The results presented in Figures 2 and 3 demonstrate that
p53TAD binds tothe DBD Fbasic cleft. There are ﬁve aspartic
acid residues and two glutamic acid residues in the p53TAD
Figure 5. The calculated intensity ratios for p53TAD after the addition of (a) hRPA701–168,( b) R41E and (c) Y118A.
2068 Nucleic Acids Research, 2005, Vol. 33, No. 7sequence between residues 39 and 59. Of these seven negat-
ively charged residues, ﬁve of them have an intensity ratio that
is >10 in the binding experiment between p53TAD and
hRPA701–168 as shown in Figure 5a. To examine the role
of electrostatics on p53TAD–hRPA701–168 complex forma-
tion, an hRPA701–168 mutant that changed the basic cleft
residue R41 to glutamic acid, R41E, was constructed and
overexpressed. It is expected that the R41E mutation will
signiﬁcantly disrupt the electrostatic character of the basic
cleft. It changes a positively charged residue into a negative
one,which couldinteractwith the otherﬁvepositivelycharged
residues in the basic cleft and could also be repulsive for the
negatively charged residues of p53TAD. A
1H–
15N HSQC
spectrum was collected to verify that R41E was folded and
no dramatic structural changes occurred relative to wild-type
hRPA701–168 (data not shown).
1H–
15N HSQC experiments
were performed on uniformly
15N-labeled samples ofp53TAD
before and after the addition of equimolar amounts of R41E.
As expected, the R41E mutant binds weakly to p53TAD. The
results in Figure 5b show small resonance intensity changes
for all p53TAD residues after the addition of R41E. All of the
intensity ratio values for the R41E experiment are below 2.0
except for residues I50-F54 which have a mean value of
3.3 – 1.7. The lack of binding between p53TAD and R41E
demonstrates the importance of electrostatics for p53TAD–
hRPA701–168 complex formation.
Additional regions of hRPA701–168 involved in
complex formation
HRPA701–168 contains the DBD F domain as well as a ﬂexible
linker between residues 105 and 168. Previous experiments
have found one detectable NOE between the ﬂexible linker
and the DBD F (9). This NOE is between the ﬂexible linker
residue Y118 and the DBD F residue T52. In the titration
experiments presented in Figures 2 and 3, T52 has an average
chemical shift change of 0.02 p.p.m. and Y118 has an average
chemical shift change of 0.06 p.p.m. A large chemical shift,
such as 0.06 p.p.m. for Y118, is expected for residues involved
in complex formation. To determine if Y118 is important for
p53TAD–hRPA701–168 complex formation, an hRPA701–168
mutant that changed Y118 to alanine, Y118A, was overex-
pressed and puriﬁed. Similar to R41E, a
1H–
15N HSQC spec-
trum was collected to verify that this mutant was folded and
no dramatic structural changes occurred relative to wild-type
hRPA701–168 (data not shown). To determine whether the
elimination of Y118 signiﬁcantly affected complex formation,
a
1H–
15N HSQC experiment was performed on an uniformly
15N-labeled sample of p53TAD after the addition of an equi-
molar amount of Y118A. The intensity ratios were determined
and plotted identically to the wild-type hRPA701–168 experi-
ment and are shown in Figure 5c. The Y118A mutant binding
is signiﬁcantly diminished compared with wildtype. In wild-
type,residues 42–56 have a mean intensity ratio of 95 – 70 and
in Y118A the mean intensity ratio is 35 – 34, suggesting a
3-fold reduction in binding.
p53TAD resonance assignments and secondary
chemical shifts
NMR resonance assignments correlate discrete signals
observed in the NMR frequency spectrum of the protein
with speciﬁc amino acid residues and they are very sensitive
to changes in protein structure and dynamics. The observed
NMR frequencies in the protein are referenced against some
appropriate standard to generate a quantity called the chemical
shift. The chemical shifts of
13C
a,
13C
b,
13CO and
1H
a nuclei
can be used to make a rapid, semi-quantitative identiﬁcation
of protein secondary structure (63–66). This method has been
widely applied to IUPs, such as p53TAD, with some general
observations worth noting (67,68). Many IUPs do not have
regions of stable secondary structure in the absence of binding
partners and are rapidly interconverting between an unspeci-
ﬁed number of structures. When the interconversionrate is fast
on the NMR timescale [>10
4 s
 1 (69)] the chemical shift
represents a population weighted average of the different
structures that make up the ensemble. In this case, the sec-
ondary chemical shift (Dd), which is the difference between
observed chemical shift and some appropriate residue speciﬁc
random coil chemical shift standard, can be used to provide an
estimate of the fraction of structures that are in a helical or
b-strand conformation. A less general observation from the
chemical shift analysis of IUPs is that Dd values can switch
from positive to negative several times over a short stretch of
the polypeptide sequence (70–72). A clear structural inter-
pretation for this behavior has not been proposed. In addition,
the Dd values for
13C
a,
13C
b,
13CO and
1H
a nuclei do not
always correlate for IUPs, making the unambiguous identiﬁca-
tion of transient secondary structure challenging (73).
Resonance assignments were made for the
13C
a,
13C
b,
13CO and
1H
a nuclei as well as the amide
15N and
1H nuclei of
p53TAD. The Dd values were determined for the
13C
a,
13C
b,
13CO and
1H
a nuclei of p53TAD and are plotted in
Figure 6a–d. The residue speciﬁc random coil chemical
shift standard used to calculate the Dd values in Figure 6
was developed by Wishart et al. (74) and is based on chemical
shift measurements for short peptides dissolved in 1 M urea
(pH 5.0). For
13C
a and
13CO nuclei, a positive Dd value indic-
ates a preference for a-helical structure and a negative Dd
value indicates a preference for b-strand structure (63–65).
The trend is reversed for
1H
a nuclei. For
13C
b nuclei, positive
Dd values indicate the presence of b-strand structure, Dd val-
ues near zero indicate the presence of a-helical structure and
negative Dd values indicate the presence of structures with
positive f and y angles (64).
It is well established that p53TAD residues 18–24 form an
amphipathic a-helix when bound to the MDM2 oncoprotein
(75). It is also well established that unbound IUPs, such as
p53TAD, will often show some preference for the secondary
structure that is observed when they form a protein complex
(76). In keeping with this principle, the
1H
a Dd values plotted
in Figure 6d suggest the presence of a transient a-helix span-
ning residues 18–24. This result conﬁrms earlier work that
reported a transient a-helix between residues 18 and 26
using
1H
a chemical shifts as well as three bond coupling
constants (43). Interestingly, the Dd values for the
13CO
and
13C
a nuclei do not show a strong preference for helical
structure for residues 18–24 and the trend observed for the
13C
b Dd values suggest a mixture of a-helix and structures
with positive f and y angles for residues 13–28 (64).
The
13C
a and
13CO Dd values suggest that the DBD F
binding site (residues 39–59) contains a mixture of a-helical,
b-strand and random coil structures. For both
13C
a and
13CO,
Nucleic Acids Research, 2005, Vol. 33, No. 7 2069Figure 6. Plotsshowingsecondarychemicalshiftsforp53TADbasedon resonanceassignments obtainedat298K.Therandomcoilchemicalshiftstandardused in
the analysis was developed by Wishart et al. (74). (a) Plot of
13C
a Dd values, (b) plot of
13C
b Dd values, (c) plot of
13CO Dd values and (d) plot of
1H
a Dd values.
2070 Nucleic Acids Research, 2005, Vol. 33, No. 7a transition from positive to negative Dd values is observed
between I50 and Q52. The
1H–
15N HSQC resonances for E51
and Q52 are the ﬁrst to disappear during the titration of
15N-
labeled p53TAD, suggesting that these residues are strongly
interacting with the DBD F basic cleft (data not shown). The
data presented in Figure 6 show some evidence for transient a-
helical and b-strand secondary structure in the DBD F binding
region of p53TAD. To determine whether this transient sec-
ondary structure is stabilized upon binding, HNCACB experi-
ments were performed on p53TAD in the presence of
increasing amounts of unlabeled hRPA701–168. The results
from these experiments showed no
13C
a and
13C
b chemical
shift changes before the resonances became too weak to detect
(data not shown).
Relaxation measurements and reduced spectral
density mapping for free and bound p53TAD
NMR relaxation measurements can be used to identify the
residue speciﬁc changes in rotational diffusion that occur
when two proteins form a complex. A standard suite of
15N
relaxation experiments was collected on free p53TAD and the
p53TAD–hRPA701–168 complex at a stoichiometry of 4:1. At
this stoichiometry, the majority of
1H–
15N HSQC resonances
are still observed for p53TAD residues in the DBD F binding
region (data not shown). Table 1 shows the mean values of R1,
R2, R1r and the
1H–
15N NOE (NHNOE) for free and bound
p53TAD. These four relaxation measurements vary systemat-
ically with the rate of rotational diffusion and provide a very
sensitive way to discriminate between folded and unfolded
regions in a protein. For instance, the mean values of R1,
R2, R1r and the NHNOE for free p53TAD are consistent
with values expected for an intrinsically unstructured protein
(67).R2is also sensitive toslower motions, likeprotein folding
or chemical exchange.
Figure 7a–d shows plots of the
15N relaxation rates R1, R2,
R1r and the NHNOE for free and bound p53TAD using open
and closed circles, respectively. Figure 7b and c show that
large changes in R2 and R1r are observed for several residues
in the binding region when free and bound p53TAD are com-
pared. Observing differences between these two relaxation
rates is one of the ﬁrst steps in discriminating between changes
in relaxation that are induced by changes in rotational dif-
fusion versusslower processeslike proteinfoldingor chemical
exchange. Figure 7b and c also shows that no signiﬁcant
changes in R2 and R1r occur for residues 1–35 and 62–73
when free and bound p53TAD are compared. This means
that residues 1–35 and 62–73 remain unfolded and do not
participate in complex formation.
For residues with a large chemical exchange contribution to
relaxation, R2 should be greater than R1r (77). This is the case
forresidues42,45,48,50and55.Other residuesinthe binding
interface that have similar values of R2 and R1r include 46, 49,
53/54, 56 and 57. It was not possible to accurately measure
R2 and R1r for residues 51 and 52 at the 4:1 stoichiometry.
We hypothesize that the pattern of large R2 and R1r values
observed for residues 42, 45, 48 and 50, represent points of
contact between these residues and DBD F. If this is the case,
then the large R2 and R1r values observed for every third
residue (42, 45 and 48) may represent the formation of two
turns of a 3
10 helix. This conclusion is supported by the small
helical Dd values observed for residues 42, 45 and 48 (see
Figure 6a). The pattern of R2 and R1r values observed for
residues C-terminal of 48 suggests that binding occurs in an
extended conformation.
The relaxation data for free and bound p53TAD was ana-
lyzed using the reduced spectral density mapping approach of
Farrow et al. (78). Reduced spectral density mapping is useful
for estimating the timescale of molecular motions occurring
at three different frequencies, the zero frequency, the
15N
resonance frequency and the
1H resonance frequency. The
reduced spectral density function at zero frequency, J(0), is
correlated with global rotational tumbling, the reduced spec-
tral density function at the
15N resonance frequency, J(wN), is
correlatedwith fastersegmental motionsandthe reduced spec-
tral density function at the
1H resonance frequency, J(wH), is
correlated with even faster internal motions like bond vector
ﬂuctuations. The statistics summarizing the reduced spectral
density mapping values at 0, wN and wH frequencies for free
and bound p53TAD are listed in Table 1. Figure 8a–c shows
plots of J(0), J(wN) and J(wH) for free and bound p53TAD
using open and closed circles, respectively. The J(0) values
plotted in Figure 8a were calculated using the R2 values from
Figure 7b and, therefore, contain contributions from chemical
exchange. J(0) values were also calculated substituting the
R1r values in Figure 7c for R2 (data not shown). J(0) values
calculated using R1r are 20–30% smaller for residues 42, 45,
48 and 50 than those calculated using R2. The differences in
J(0) can be used to estimate the exchange term, Rex (58). For
residue 50, the value of J(0) calculated using R2 is 8.78 ns and
the value calculated using R1r is 6.07 ns. This difference of
2.71 ns corresponds to an Rex value of 8.36 s
 1. Residues 42,
45 and 48 have Rex values in the range of 1–10 s
 1 (data not
shown). Values of Rex in the range of 1–10 s
 1 have been
observed for protein folding intermediates and conformational
ﬂuctuations that occur on the timescale of protein folding
(79–81). The large Rex values observed for residues 42, 45,
48 and 50 suggest that the DBD F binding region of p53TAD
undergoes a folding transition upon binding.
CONCLUSIONS
Over the past decade, signiﬁcant controversy has arisen con-
cerning the functional signiﬁcance of the p53–hRPA70 inter-
action. In vitro binding studies have shown that p53 and
hRPA70 form a complex that can inhibit p53 from site-
speciﬁc DNA binding and transcriptional activation (22,24).
This inhibition is relieved in the presence of ssDNA (24). It is
also known that hRPA70 has a higher afﬁnity for ssDNA than
for p53 and the addition of ssDNA causes the release of p53
from a preformed p53–hRPA70 complex (19,24,82). Based on
Table 1. Statistics for relaxation and reduced spectral density mapping data
p53TAD p53TAD + hRPA701–168
R1 1.74 – 0.22 1.69 – 0.23
R2 3.16 – 0.56 4.13 – 2.21
R1r 3.81 – 0.66 4.55 – 1.45
NHNOE  0.64 – 0.95  0.51 – 0.75
J(0) 1.61 – 0.36 2.33 – 1.62
J(wN) 0.74 – 0.15 0.72 – 0.14
J(wH) 0.064 – 0.037 0.058 – 0.029
Nucleic Acids Research, 2005, Vol. 33, No. 7 2071Figure 7. Plotsshowingrelaxationdataforp53TAD(opencircles)andp53TADplusunlabeledhRPA701–168(closedcircles).(a)Plotofthelongitudinalrelaxation
rates, R1, labeled R1; (b) plot of the transverse relaxation rates, R2, labeled R2; (c) plot of the rotating frame relaxation rates, R1r, labeled R1rho; and (d) plot of the
1H–
15NNOElabeledNHNOE.Errorbarsareshownforthenoisiestdatasets,whichinallcasesisforboundp53TAD.Formostofthep53TADresidues,errorvalues
are smaller than the data markers.
2072 Nucleic Acids Research, 2005, Vol. 33, No. 7these observations, Prives and co-workers (24,27) have sug-
gested that the p53–hRPA70 complex provides a reservoir of
p53that isimmediatelyavailabletocontrolthe transcriptionof
DNA repair, apoptosis and growth arrest genes when released
from hRPA70. This hypothesis is consistent with the
observation that hRPA isolated from UV-treated cells does
not bind p53, suggesting that complex formation is regulated
by the presence of DNA damage and perhaps the phosphoryla-
tion of hRPA32 (21,83,84). According to Abramova et al.
(21), the p53–hRPA70 interaction plays a role in linking
Figure8.Plotsofreducedspectraldensitymappingdataforp53TAD(opencircles)andp53TADplusunlabeledhRPA701–168(closedcircles).(a)Plotofthespectral
densityatzerofrequency,J(0),labeledJ(w0);(b)plotofthespectraldensityatthe
15Nfrequency,J(wN),labeledJ(wN);and(c)plotofthespectraldensityatthe
1H
frequency,J(wH),labeledJ(wH).Errorbarsareshownforthenoisiestdatasets,whichinallcasesisforboundp53TAD.Formostofthep53TADresidues,errorvalues
are smaller than the data markers.
Nucleic Acids Research, 2005, Vol. 33, No. 7 2073p53 to DNA damage. They observed that UV radiation
disrupts the p53–hRPA70 interaction in a dose- and time-
dependent manner. Furthermore, the disruption of p53–
hRPA70 binding was correlated with the ability of damaged
cells to perform global genomic repair. These results suggest
that after UV irradiation the hRPA heterotrimer participates
in nucleotide excision repair and simultaneously releases the
bound p53 (21). This idea is consistent with the role of
hRPA70 in the early stages of nucleotide excision repair
(85). hRPA70 binds to the ssDNA exposed by open complex
formation using DBD A and DBD B and may bind directly to
the damaged site using DBD C (17,18). At some point during
this recognition process p53 will disassociate from hRPA70.
In this report we present evidence that p53TAD and
hRPA701–168 are sufﬁcient for complex formation. Further,
results are presented which show that p53TAD binds to the
DBD F basic cleft. In summation, the results of this paper
provide support for the hypothesis that p53TAD and ssDNA
compete for an overlapping binding site on the DBD F basic
cleft. NMR experiments in this paper demonstrate the import-
ance of electrostatics for the binding of p53TAD to the basic
cleft. A single mutation in a basic cleft residue, R41E, is
sufﬁcient for eliminating binding. Further, a mutation in the
hRPA701–168 linker, Y118A, has diminished binding. A recent
studyin this laboratory has proposed a new model for the DBD
F structure that incorporates the Y118–T52 interaction
(K.E. Olson, P.D. Vise, P. Narayanaswami, D.F. Lowry,
M.S. Wold and G.W. Daughdrill, manuscript in preparation).
Inthismodel,hRPA70linkerresiduesbetweenY118andA128
are in a position to occlude the basic cleft and possibly provide
an additional layer of regulation for interactions with the basic
cleft.
1H–
15N HSQC experiments were performed demonstrat-
ing that the region between p53TAD residues 39 and 59
had the largest change in resonance intensity and are the
residues responsible for forming the binding interface with
hRPA701–168.Nodifferenceswere seeninthe secondary struc-
ture of p53TAD in the presence and absence of hRPA701–168.
However, a p53TAD-binding site identiﬁed by NMR analysis
in this paper was shown to have some residual a-helical and
b-strand structure. This residual secondary structure had not
been identiﬁed in earlier NMR studies.
NMR titrations are a very powerful tool for the analysis of
protein–protein interactions. In addition to identifying the
binding interface, NMR titrations can provide information
about the kinetics and thermodynamics of the interaction
(62). When resonances change their position, similar to
those observed in the HSQC spectrum of
15N-labeled
hRPA701–168 after the addition of unlabeled p53TAD, the
rate of exchange between the free and bound structures is
fast with an exchange rate constant, k, on the order of 10
3–
10
4 s
 1 (69). When resonances lose intensity with no apparent
chemical shift changes, similar to those observed for
15N-labeled p53TAD after the addition of unlabeled
hRPA701–168, the rate of exchange between the free and
bound structures is intermediate with a value for k on the
order of 10
2–10
3 s
 1. These well-established relationships
between resonance behavior and rates of exchange facilitate
an explanation for the differences in the NMR titration results
presented in Figures 2 and 4. Because the same proteins are
binding one another, the same type of chemical shift changes
in the HSQC resonances should be observed regardless of
which protein is
15N-labeled. There must be some additional
process that is slowing down the exchange rate between the
free and the bound forms of p53TAD when compared with
hRPA701–168. One obvious process that would slow down
complex formation is the folding of p53TAD. The effect of
this folding would only be observed when the HSQC
resonancesof
15N-labeledp53TADaremonitored.Itisunclear
as to exactly what structure of p53TAD is formed when it
binds to DBD F. Further, folding could simply describe a
rigidly held form of p53TAD that is an extended conforma-
tion. Using NMR relaxation measurements and reduced spec-
tral density mapping, we have identiﬁed a large chemical
exchange contribution to the
15N transverse relaxation rates
(R2) of p53TAD residues that form the binding interface with
hRPA701–168. Based on the argument presented above it is
likely that this chemical exchange contribution to
15N trans-
verse relaxation is due to the folding of p53TAD.
Since p53TAD is highly acidic (pI = 3.77) and DBD F
contains a positively charged cleft with ﬁve arginines and
one lysine, it is reasonable to expect that electrostatics will
play a prominent role in p53TAD–DBD F complex formation
and that the acidic residues in p53TAD will have a favorable
electrostatic interaction with the basic cleft. This hypothesis is
strongly supported by the data presented in Figures 3 and 5.
Based on the distribution of negatively charged amino acid
pairs in the primary sequence of p53TAD (see Figure 1), it is
possible that this favorable electrostatic interaction occurs
between one pair of negatively charged residues in p53TAD
and the positively charged DBD F basic cleft. This will result
in the formation of an encounter complex that can then under-
go a structural rearrangement to optimize the stability of the
complex. This hypothesis assumes that the formation of the
encounter complex represents a dynamically bound state for
p53TAD that allows the protein to ‘check the binding site’
using the peptide segments that are adjacent to the pair of
negative residues. If favorable van der Waals and hydrogen
bonding interactions are available, then a tighter complex will
be formed. If no favorable interactions are encountered then a
new binding site will be ‘checked’ at the next pair of negative
residues. If the energetics of encounter complex formation are
dominated by ionic interactions between the negatively
charged pairs and the basic cleft, then all of the encounter
complexes will have similar afﬁnities.
A simpliﬁed model based on the overlapping p53TAD and
ssDNA-binding sites identiﬁed on DBD F is illustrated in
Figure 9. We hypothesize that before DNA damage is detec-
ted, p53 is bound to hRPA70. Data presented in this report
provide strong evidence for the interaction between p53TAD
and DBD F that is shown in Figure 9. The interaction between
the C-terminal regulatory domain of p53 and the DBD C is
more speculative. After DNA damage is detected, DBD A and
B will bind with high afﬁnity to the ssDNA that is exposed
during formation of the open complex. When this occurs, the
ﬂexibility and length of the linker will determine the orienta-
tion and mobility of DBD F relative to ssDNA. According to
our model, this linkage effect will increase the afﬁnity of DBD
F for ssDNA by increasing the local concentration of ssDNA.
The increased afﬁnity between DBD F and ssDNA will result
in the disassociation of p53 from hRPA70. It is unclear what
p53 does after it is released from hRPA70. It is tantalizing to
speculate that p53 will activate the transcription of apoptosis
2074 Nucleic Acids Research, 2005, Vol. 33, No. 7and growth arrest genes to amplify the cellular response to
DNA damage.
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